English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background  In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase ( pfdhfr ) and dihydropteroate synthase ( pfdhps ) genes.    Methods  In samples from 86 patients with uncomplicated  Plasmodium falciparum  malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the  pfcrt  and  pfmdr1  genes which are associated with CQ resistance and in  pfdhfr  and  pfdhps , conferring SP resistance, as well in  cytb  which is linked to resistance to atovaquone.    Results   Pfcrt  T76 occurs in 50% and  pfmdr1  Y86 in 51.7%.  Pfdhfr  triple mutations coexisting with  pfdhps  double mutations were detected in 64.3% of the  P. falciparum  isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the  cytb  gene were not detected.    Conclusion  These findings of a high prevalence of mutations conferring SP resistance correspond to data of  in vivo  SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.

Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania